- Home
- RDZN vs LUNG Comparison
RDZN vs LUNG Comparison
Compare RDZN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDZN
- LUNG
- Stock Information
- Founded
- RDZN 2015
- LUNG 1995
- Country
- RDZN United States
- LUNG United States
- Employees
- RDZN N/A
- LUNG N/A
- Industry
- RDZN Blank Checks
- LUNG Industrial Specialties
- Sector
- RDZN Finance
- LUNG Health Care
- Exchange
- RDZN Nasdaq
- LUNG Nasdaq
- Market Cap
- RDZN 113.7M
- LUNG 106.3M
- IPO Year
- RDZN N/A
- LUNG 2020
- Fundamental
- Price
- RDZN $1.29
- LUNG $3.09
- Analyst Decision
- RDZN Strong Buy
- LUNG Buy
- Analyst Count
- RDZN 2
- LUNG 6
- Target Price
- RDZN $5.00
- LUNG $11.53
- AVG Volume (30 Days)
- RDZN 566.9K
- LUNG 401.8K
- Earning Date
- RDZN 08-12-2025
- LUNG 07-30-2025
- Dividend Yield
- RDZN N/A
- LUNG N/A
- EPS Growth
- RDZN N/A
- LUNG N/A
- EPS
- RDZN N/A
- LUNG N/A
- Revenue
- RDZN $44,296,098.00
- LUNG $87,473,000.00
- Revenue This Year
- RDZN $39.09
- LUNG $18.02
- Revenue Next Year
- RDZN $65.61
- LUNG $18.17
- P/E Ratio
- RDZN N/A
- LUNG N/A
- Revenue Growth
- RDZN N/A
- LUNG 19.84
- 52 Week Low
- RDZN $0.68
- LUNG $2.50
- 52 Week High
- RDZN $2.99
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- RDZN 59.82
- LUNG 50.76
- Support Level
- RDZN $1.03
- LUNG $2.99
- Resistance Level
- RDZN $1.55
- LUNG $3.88
- Average True Range (ATR)
- RDZN 0.11
- LUNG 0.35
- MACD
- RDZN 0.04
- LUNG 0.07
- Stochastic Oscillator
- RDZN 57.85
- LUNG 39.23
About RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.